SYGGF (Synairgen) Accounts Payable: $0.97 Mil (As of Dec. 2024)


What is Synairgen Accounts Payable?

Synairgen SYGGF Accounts Payable is $0.97 Mil as of Dec. 2024.

Synairgen's Accounts Payable for the quarter that ended in Dec. 2024 was $0.97 Mil.

Synairgen's quarterly Accounts Payable increased from Dec. 2023 ($0.75 Mil) to Jun. 2024 ($1.37 Mil) but then declined from Jun. 2024 ($1.37 Mil) to Dec. 2024 ($0.97 Mil).

Synairgen's annual Accounts Payable increased from Dec. 2022 ($0.67 Mil) to Dec. 2023 ($0.75 Mil) and increased from Dec. 2023 ($0.75 Mil) to Dec. 2024 ($0.97 Mil).

Synairgen Accounts Payable Historical Data

* Premium members only.

The historical data trend for Synairgen's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Synairgen Accounts Payable Chart

Synairgen Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.07 5.53 0.67 0.75 0.97

Synairgen Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.67 3.46 0.75 1.37 0.97

Synairgen Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $0.97 Mil mean?
Synairgen (SYGGF) has a Accounts Payable of $0.97 Mil as of Dec. 2024. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Synairgen and its competitors.
Is Synairgen's Accounts Payable too high?
Synairgen's current Accounts Payable is $0.97 Mil.
How does Synairgen's Accounts Payable compare to RGBP and CNBX?
Synairgen's Accounts Payable of $0.97 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Synairgen and its competitors. Synairgen's current Accounts Payable is $0.97 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synairgen stock overvalued right now?
Synairgen (SYGGF) has a current Accounts Payable of $0.97 Mil. The current Accounts Payable is $0.97 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Synairgen (SYGGF), the current Accounts Payable is $0.97 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Synairgen Business Description

Address Southampton General Hospital, Tremona Road, Mailpoint 810, Level F, South Block, Southampton, GBR, SO16 6YD
Synairgen PLC is a United Kingdom-based respiratory drug discovery and development company. The company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in areas including severe asthma, kidney fibrosis, cardiac fibrosis, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis. The company's Programmes include SNG001, SG016, SG018, and others.